LeMaitre Vascular (LMAT) director gains new stock through awards

Rhea-AI Filing Summary

LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.

Insider Trade Summary

1 shares exercised/converted

Mixed 3 txns

Insider Ross Bridget A

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	1	$0.00	--
Grant/Award	Common Stock	476	$0.00	--
Exercise	Common Stock	1	$0.00	--

Holdings After Transaction: Dividend Equivalent Rights — 2.896 shares (Direct); Common Stock — 3,941 shares (Direct)

Footnotes (1)

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Bridget A

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		476(1)	A	$0	3,941	D
Common Stock	02/26/2026		M		1(2)	A	$0(2)	3,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(3)	02/26/2026		M			1(3)	(3)	(3)	Common Stock	1	$0	2.8963	D

Explanation of Responses:

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years.

2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

3. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LeMaitre Vascular (LMAT) director Bridget A. Ross report on this Form 4?

Bridget A. Ross reported acquiring LeMaitre Vascular common stock through equity awards. She received 476 shares from the vesting of a performance share unit award and 1 share from dividend equivalent rights, increasing her directly held stake to 3,942 shares.

How many LeMaitre Vascular (LMAT) shares did Bridget A. Ross acquire on February 26, 2026?

Ross acquired 477 LeMaitre Vascular-related shares in total-linked transactions. This included 476 shares of common stock from a performance share unit vesting and 1 share of common stock released from dividend equivalent rights tied to that award.

What are performance share units (PSUs) mentioned in the LeMaitre (LMAT) Form 4 filing?

The Form 4 shows common stock delivered upon settlement of a performance share unit award. A PSU granted on December 6, 2024 vested one-third after the performance condition was determined satisfied on February 26, 2026, with the remaining shares vesting in equal annual installments over the next two years.

What are dividend equivalent rights in the LeMaitre Vascular (LMAT) insider transaction?

Dividend equivalent rights in this filing are economic equivalents of common stock. The Form 4 notes that each dividend equivalent right corresponds one-for-one with a share of LeMaitre Vascular common stock and was released in connection with the vesting of the related PSU award.

How many LeMaitre Vascular (LMAT) shares does Bridget A. Ross own after these transactions?

Following the reported equity award activity, Ross directly holds 3,942 LeMaitre Vascular shares. This figure reflects the additional common stock from the PSU vesting and the release of dividend equivalent rights reported in the Form 4 transactions.

Were the LeMaitre Vascular (LMAT) shares bought on the open market in this Form 4?

No, the reported acquisitions arose from equity awards, not open-market purchases. The filing characterizes the transactions as a grant or award acquisition and exercises or conversions of derivative securities linked to performance share units and dividend equivalent rights.